ChiCTR2500100290 版本V1.0 版本创建时间2025/04/07 15:59:06 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500100290 

最近更新日期:

Date of Last Refreshed on:

2025-04-07 15:58:59 

注册时间:

Date of Registration:

2025-04-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

梅尼埃病的分子遗传机制研究

Public title:

Research on the molecular genetic mechanism of Meniere's disease.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

梅尼埃病的分子遗传机制研究

Scientific title:

Research on the molecular genetic mechanism of Meniere's disease.

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐晓川 

研究负责人:

王洪阳 

Applicant:

Xu Xiaochuan 

Study leader:

Wang Hongyang 

申请注册联系人电话:

Applicant telephone:

+86 186 2493 3890

研究负责人电话:

Study leader's
telephone:

+86 183 1108 1809

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hd1131144202@163.com

研究负责人电子邮件:

Study leader's E-mail:

whyx301@foxmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区复兴路28号

研究负责人通讯地址:

北京市海淀区复兴路28号

Applicant address:

No.28 Fuxing Road, Haidian District, Beijing

Study leader's address:

No.28 Fuxing Road, Haidian District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国人民解放军总医院

Applicant's institution:

General Hospital of the Chinese People's Liberation Army

研究负责人所在单位:

中国人民解放军总医院

Affiliation of the Leader:

General Hospital of the Chinese People's Liberation Army

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审第S2025-094-01号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军总医院医学伦理委员会

Name of the ethic committee:

Ethics Commitee Of Chinese PLA General Hosptial

伦理委员会批准日期:

Date of approved by ethic committee:

2025-02-27 00:00:00

伦理委员会联系人:

曹汪

Contact Name of the ethic committee:

Cao Wang

伦理委员会联系地址:

北京市海淀区复兴路28号

Contact Address of the ethic committee:

No.28 Fuxing Road, Haidian District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6693 7166

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国人民解放军总医院

Primary sponsor:

General Hospital of the Chinese People's Liberation Army

研究实施负责(组长)单位地址:

北京市海淀区复兴路28号

Primary sponsor's address:

No.28 Fuxing Road, Haidian District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院

具体地址:

北京市海淀区复兴路28号

Institution
hospital:

General Hospital of the Chinese People's Liberation Army

Address:

No.28 Fuxing Road, Haidian District, Beijing

经费或物资来源:

课题基金

Source(s) of funding:

Subject Fund

研究疾病:

梅尼埃病  

Target disease:

Meniere's disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

针对梅尼埃病的临床诊疗瓶颈,本研究将围绕“梅尼埃病遗传机制不清和诊断依据有限”这一问题,开展一项病例系列研究,构建梅尼埃病样本数据库,整合分析临床特征及基因组、转录组和表观遗传学等多组学信息,探究梅尼埃病病因及分子遗传机制,探索特异性诊断标志物并构建预后预测模型,进一步提升梅尼埃病的预测评估及诊疗水平  

Objectives of Study:

To address the bottleneck of clinical diagnosis and treatment of Ménière's disease, this study will focus on the problem of ‘unclear genetic mechanism and limited diagnostic basis of Ménière's disease’, carry out a case series study, construct a database of Ménière's disease samples, integrate and analyse the clinical characteristics and multi-omics information such as genomes, transcriptomes, and epigenomes, and explore the cause and molecular genetic mechanism of Ménière's disease. To explore the molecular genetic mechanism of Ménière's disease, explore specific diagnostic markers and construct prognostic models, so as to further improve the prediction and assessment of Ménière's disease and diagnosis and treatment of the disease.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

年龄大于 18岁;符合梅尼埃病诊断标准:1.2次或2 次眩晕发作,每次持续20min至12h;2.病程中至少有一次听力学检查证实患耳有低到中频的感音神经性听力下降;3.患耳有波动性听力下降、耳鸣和(或)耳闷胀感;4.排除其他前庭疾病引起的眩晕。

Inclusion criteria

Age greater than 18 years; Meet the diagnostic criteria for Meniere's disease: 1.2 or 2 episodes of vertigo, each lasting 20 minutes to 12 hours; 2. At least one audiological examination during the course of the disease confirms that the affected ear has low to medium frequency sensorineural hearing loss; 3. Fluctuating hearing loss, tinnitus and/or ear fullness in the affected ear; 4. Exclude vertigo caused by other vestibular disorders.

排除标准:

明确良性阵发性位置性眩晕、前庭神经炎、迷路炎、前庭阵发症、后循环缺血、颅内占位性病变等其他疾病;明确神经内科相关疾病所致眩晕患者;合并其他系统严重疾病患者。

Exclusion criteria:

Benign paroxysmal positional vertigo, vestibular neuritis, labyrinthitis, vestibular paroxysmals, posterior circulation ischemia, intracranial space-occupying lesions and other diseases were identified; identify patients with vertigo caused by neurology-related diseases; Patients with severe diseases of other systems.

研究实施时间:

Study execute time:

From 2025-02-27 00:00:00 To 2030-02-27 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-04-07 00:00:00 To 2030-02-27 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

100

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院 

单位级别:

三甲 

Institution
hospital:

General Hospital of the Chinese People's Liberation Army

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

基因检测结果

指标类型:

主要指标

Outcome:

Genetic test results

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床检查结果

指标类型:

次要指标

Outcome:

Clinical findings

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用CRF和EDC进行采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Capture using CRF and EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-04-07 15:58:59